Ultragenyx Pharmaceutical | RARE - Gross Profit On Sales


Ultragenyx Pharmaceutical reported $180M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Immunic 0 0 Mar/2025
Insmed USD 356.19M 99.73M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Kyowa Hakko Kirin JPY 109.03B 20.79B Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026